Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8130829 | 0.94 | ALDH1A1 (0.37) | ALDH1A1MAPK1GAA | |
| SCHEMBL12889782 | 0.92 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL10717480 | 0.87 | MAPK1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL22332103 | 0.87 | CYP4F2 (0.35) | ALDH1A1 | |
| Butanone SCHEMBL6320301 | 0.82 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL824022 | 0.81 | — | — | |
| SCHEMBL10932413 | 0.81 | MAPK1 (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL20314559 | 0.79 | CYP4F2 (0.35) | MAPK1 | |
| SCHEMBL20314555 | 0.79 | CYP4F2 (0.35) | MAPK1 | |
| SCHEMBL20314556 | 0.79 | CYP4F2 (0.35) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235332-A1 | TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF GENE TRANSCRIPTS | QURALIS CORPORATION | 2023-07-27 | — | — | US | disclosed |
| US-20230137245-A1 | NEW FROTHERS FOR MINERALS RECOVERY | SOLVAY SA (BE) | 2023-05-04 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-6040339-A | TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL | SANKYO COMPANY, LIMITED (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5880147-A | Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use | SANKYO COMPANY, LIMITED (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ALDH1A1 974/4885MAPK1 2929/4885GAA 511/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | ALDH1A1 132/4885MAPK1 3042/4885GAA 3888/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ALDH1A1 974/4885MAPK1 2929/4885GAA 511/4885 |
| US-20230137245-A1 | NEW FROTHERS FOR MINERALS RECOVERY | FLOT1, SFXN1, AFF1 | ALDH1A1 3036/4885MAPK1 3976/4885GAA 1995/4885 |
| US-20230235332-A1 | TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF GENE TRANSCRIPTS | STMN2, STMN1, PSEN2 | ALDH1A1 4116/4885MAPK1 4681/4885GAA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.